These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37379778)

  • 1. Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA.
    Wang C; Luo H; Chen X; Zhang Y; Lu D; Liu X; Yin F; Li S; Kong L; Wang X
    Bioorg Chem; 2023 Oct; 139():106683. PubMed ID: 37379778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
    Zhu X; Chen L; Huang B; Li X; Yang L; Hu X; Jiang Y; Shao Z; Wang Z
    J Exp Clin Cancer Res; 2021 Apr; 40(1):122. PubMed ID: 33832512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA.
    Wang C; Qu L; Li S; Yin F; Ji L; Peng W; Luo H; Lu D; Liu X; Chen X; Kong L; Wang X
    J Med Chem; 2021 Sep; 64(17):12630-12650. PubMed ID: 34455779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy.
    Li X; Wang C; Li S; Yin F; Luo H; Zhang Y; Luo Z; Chen Y; Wan S; Kong L; Wang X
    Eur J Med Chem; 2024 Feb; 265():116054. PubMed ID: 38134746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of dual-targeted molecules based on Olaparib and Rigosertib for triple-negative breast cancer with wild-type BRCA.
    Liu Z; Mao S; Dai L; Huang R; Hu W; Yu C; Yang Y; Cao G; Huang X
    Bioorg Med Chem; 2024 Nov; 113():117936. PubMed ID: 39369565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Progressively Disassembled DNA Repair Inhibitors Nanosystem for the Treatment of BRCA Wild-Type Triple-Negative Breast Cancer.
    Fang W; Wang J; Ma X; Shao N; Ye K; Zhang D; Shi C; Luo L
    Int J Nanomedicine; 2023; 18():6001-6019. PubMed ID: 37901361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
    Okuma HS; Yonemori K
    Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
    Wang J; He G; Li H; Ge Y; Wang S; Xu Y; Zhu Q
    Eur J Med Chem; 2021 Mar; 213():113054. PubMed ID: 33309164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
    Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
    Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells.
    Kawanishi M; Fujita M; Karasawa K
    Breast Cancer (Auckl); 2022; 16():11782234221080553. PubMed ID: 35340889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer.
    Pu C; Tong Y; Liu Y; Lan S; Wang S; Yan G; Zhang H; Luo D; Ma X; Yu S; Huang Q; Deng R; Li R
    Eur J Med Chem; 2022 Jun; 236():114321. PubMed ID: 35430559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.
    Karginova O; Siegel MB; Van Swearingen AE; Deal AM; Adamo B; Sambade MJ; Bazyar S; Nikolaishvili-Feinberg N; Bash R; O'Neal S; Sandison K; Parker JS; Santos C; Darr D; Zamboni W; Lee YZ; Miller CR; Anders CK
    Mol Cancer Ther; 2015 Apr; 14(4):920-30. PubMed ID: 25824335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells.
    Guney Eskiler G; Ozman Z; Haciefendi A; Cansaran-Duman D
    Naunyn Schmiedebergs Arch Pharmacol; 2023 May; 396(5):1031-1041. PubMed ID: 36598514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
    Layman RM; Arun B
    Cancer J; 2021 Jan-Feb 01; 27(1):67-75. PubMed ID: 33475295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
    Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
    Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
    Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
    Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.